Stock DNA
Pharmaceuticals & Biotechnology
INR 135 Cr (Micro Cap)
15.00
19
0.00%
0.83
8.82%
1.35
Total Returns (Price + Dividend) 
Parnax Lab for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Parnax Lab Ltd is Rated Strong Sell
Parnax Lab Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 07 September 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 19 November 2026, providing investors with the latest perspective on the company’s position.
Read More
Parnax Lab Ltd Valuation Shifts to Very Attractive Amid Mixed Returns
Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a very attractive rating. Despite recent price pressures and a mixed performance relative to the Sensex, the stock’s improved price-to-earnings and price-to-book ratios suggest a potential revaluation opportunity for investors willing to navigate its risk profile.
Read More
Parnax Lab Ltd is Rated Strong Sell
Parnax Lab Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 07 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 October 2026, providing investors with the most recent and relevant data to assess the company’s outlook.
Read More Announcements 
Board Meeting Intimation for Consideration And Approval Of Financial Results Along With Limited Review Report For The Quarter (Q2) And Half Year Ended 30Th September 2026.
03-Nov-2026 | Source : BSEParnax Lab Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2026 inter alia to consider and approve Standalone and Consolidated Un-audited IND- AS Compliant Financial Results along with Limited Review Report for the quarter (Q2) and half year ended 30th September 2026 pursuant to Regulation 33 of Listing Obligation and Disclosure Requirement 2015.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
14-Oct-2026 | Source : BSEPlease find enclosed herewith the confirmation certificate from RTA under Reg. 74 (5) of SEBI (DP) Regulations 2018.
Shareholder Meeting / Postal Ballot-Scrutinizers Report
30-Sep-2026 | Source : BSEPlease find enclosed herewith the Voting results of AGM held on 29.09.2026
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
9.4112
Held by 0 Schemes
Held by 0 FIIs
Prakash Mahasukhlal Shah (13.61%)
Suman Gupta (1.62%)
22.71%
Quarterly Results Snapshot (Consolidated) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 21.94% vs -18.43% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 406.98% vs -80.28% in Jun 2026
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 17.77% vs 7.81% in Sep 2024
Growth in half year ended Sep 2025 is -6.63% vs 42.39% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 29.00% vs -2.56% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 11.74% vs 16.69% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 32.39% vs -0.51% in Mar 2025
YoY Growth in year ended Mar 2026 is 2.26% vs 19.88% in Mar 2025